Evolus, Inc. (EOLS): Price and Financial Metrics

Evolus, Inc. (EOLS): $13.61

1.74 (+14.66%)

POWR Rating

Component Grades














  • EOLS scores best on the Value dimension, with a Value rank ahead of 63.56% of US stocks.
  • EOLS's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • EOLS ranks lowest in Momentum; there it ranks in the 12th percentile.

EOLS Stock Summary

  • Of note is the ratio of Evolus Inc's sales and general administrative expense to its total operating expenses; 98.7% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -45.96%, Evolus Inc's debt growth rate surpasses only 8.58% of about US stocks.
  • As for revenue growth, note that EOLS's revenue has grown 76.29% over the past 12 months; that beats the revenue growth of 88.92% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Evolus Inc are KE, AMSF, CURI, TTCF, and AMPG.
  • EOLS's SEC filings can be seen here. And to visit Evolus Inc's official web site, go to www.evolus.com.

EOLS Valuation Summary

  • EOLS's EV/EBIT ratio is -3.8; this is 112.97% lower than that of the median Healthcare stock.
  • Over the past 43 months, EOLS's price/sales ratio has gone NA NA.
  • Over the past 43 months, EOLS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for EOLS.

Stock Date P/S P/B P/E EV/EBIT
EOLS 2021-08-31 7.6 5.5 -4.4 -3.8
EOLS 2021-08-30 7.5 5.4 -4.4 -3.8
EOLS 2021-08-27 7.6 5.5 -4.5 -3.8
EOLS 2021-08-26 7.7 5.5 -4.5 -3.8
EOLS 2021-08-25 7.9 5.7 -4.6 -4.0
EOLS 2021-08-24 7.9 5.7 -4.6 -4.0

EOLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EOLS has a Quality Grade of C, ranking ahead of 44.26% of graded US stocks.
  • EOLS's asset turnover comes in at 0.373 -- ranking 125th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows EOLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.373 0.630 -3.772
2021-03-31 0.300 0.674 -1.580
2020-12-31 0.271 0.676 -1.214
2020-09-30 0.256 0.735 -0.356
2020-06-30 0.245 0.734 -0.491
2020-03-31 0.216 0.731 -0.603

EOLS Price Target

For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.14 Average Broker Recommendation 1.57 (Moderate Buy)

EOLS Stock Price Chart Interactive Chart >

Price chart for EOLS

EOLS Price/Volume Stats

Current price $13.61 52-week high $14.34
Prev. close $11.87 52-week low $5.06
Day low $11.84 Volume 778,123
Day high $13.76 Avg. volume 507,067
50-day MA $11.55 Dividend yield N/A
200-day MA $8.73 Market Cap 762.83M

Evolus, Inc. (EOLS) Company Bio

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.

EOLS Latest News Stream

Event/Time News Detail
Loading, please wait...

EOLS Latest Social Stream

Loading social stream, please wait...

View Full EOLS Social Stream

Latest EOLS News From Around the Web

Below are the latest news stories about Evolus Inc that investors may wish to consider to help them evaluate EOLS as an investment opportunity.

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 24, 2022

Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.

Business Wire | February 17, 2022

Evolus (EOLS) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

Evolus'' request to market anti-wrinkle therapy accepted in Australia

Evolus <> announced on Tuesday that the Australian Therapeutics Good Administration ((TGA)) accepted its submission seeking the regulatory approval of Nuceiva

Seeking Alpha | February 8, 2022

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®

NEWPORT BEACH, Calif., February 08, 2022--Evolus announces the acceptance of its submission to the Australian Therapeutics Good Administration for regulatory approval of Nuceiva®

Yahoo | February 8, 2022

Read More 'EOLS' Stories Here

EOLS Price Returns

1-mo 18.14%
3-mo 47.29%
6-mo 138.77%
1-year 25.67%
3-year -6.20%
5-year N/A
YTD 109.06%
2021 93.75%
2020 -72.39%
2019 2.27%
2018 N/A
2017 N/A

Continue Researching EOLS

Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:

Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6267 seconds.